French soccer giant Paris Saint-Germain has agreed on a multi-year exclusive licensing agreement for the production of trading cards and stickers with sports collectibles specialist Topps.
The first PSG products are set to launch imminently.
Topps claims that the new agreement will enable it to expand and develop its distribution network in France beyond its existing newsagent presence, to become a major player in the trading card industry.
The agreement adds to Topps' soccer portfolio, which already includes the Bundesliga, the Uefa Champions League, and the Euro 2024 national team soccer championships.
PSG and Fanatics already have a ten-year, "multi-million dollar" partnership that covers major e-commerce, manufacturing, and licensing.
Topps was acquired by Fanatics in January for a reported $500 million.


Trump, Canada Reach Gordie Howe Bridge Deal Ahead of July 27 Opening
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
6 simple questions to tell if a ‘finfluencer’ is more flash than cash
Asian Stocks Rise as AI Chip Rally Offsets Middle East Tensions
How to support someone who is grieving: five research-backed strategies
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
FBI Faces Historic Security Challenge Ahead of 2026 FIFA World Cup
Why have so few atrocities ever been recognised as genocide?
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Yes, government influences wages – but not just in the way you might think
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Heritage, desire and diplomacy: why China still values scotch whisky
Trump’s U.S. Open Visit Delays Final, Fans Face Long Security Lines
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 



